ClinicalTrials.gg
CompletedNCT06280768Updated Aug 10, 2026

Study on the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2004 Injection in Adult Patients With Atrial Fibrillation

A Phase 1 interventional study of SHR-2004 injection in Atrial Fibrillation, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Completed at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 376 studies in Atrial Fibrillation with a site in China — 161 open to participants now, 182 under way, 4 of them phase 3. Atrial Fibrillation · China.

Enrollment
251st of 255
10 · median 234
Started
2024
with 44 others
Phase 1
3 of 376
1 open now
Registered
220th of 376
by date

Among the 376 studies in Atrial Fibrillation with a site in China, this one is the 251st largest by enrollment of the 255 interventional ones that give a count, is one of 45 that started in 2024, is one of 3 in phase 1, and was the 220th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

161 of the 376 studies in Atrial Fibrillation with a site in China are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 376 studies in Atrial Fibrillation with a site in China, or all of them as a file.
02

Study summary

This study is an open-label Phase Ib clinical study with the primary objective of evaluating the safety and tolerability of multiple subcutaneous injections of SHR-2004 injection in patients with atrial fibrillation, and the secondary objective is to evaluate its pharmacokinetic (PK), pharmacodynamic (PD) and immunogenicity characteristics.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand the study procedures and methods, voluntarily participate in this trial, and sign the form in writing;
  2. Male or female ≥ 40 years and \< 80 years old;
  3. History of atrial fibrillation or atrial flutter, or newly diagnosed atrial fibrillation or atrial flutter during the screening period, as documented by Holter or 12-lead ECG at the time of screening or within 12 months prior to screening.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a mechanical heart valve;
  2. Rheumatic mitral stenosis or moderate to severe non-rheumatic mitral stenosis;
  3. Atrial fibrillation or atrial flutter is caused by reversible causes, or successful ablation has been converted to sinus rhythm, or cardioversion or ablation surgery is planned during the study;
  4. Concomitant poorly controlled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100mmHg) at screening;
  5. Those who are allergic to the trial drug or any component of the trial drug;
  6. Unstable or severe liver, renal, cardiovascular, psychiatric, neurological, endocrine, hematological and other diseases at the time of screening, and the investigator judges that it is not suitable to participate in the study;
  7. Females who are pregnant or lactating.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    SHR-2004 injection

    Drug: SHR-2004 injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (including bleeding events)

    Time frame: Up to 136 Days

Secondary outcomes

  1. Pharmacokinetics of SHR2004: Peak Plasma Concentration (Cmax)

    Time frame: Up to 136 Days

  2. Pharmacokinetics of SHR2004: Area under the plasma concentration versus time curve (AUC)

    Time frame: Up to 136 Days

  3. Pharmacokinetics of Dupilumab: Elimination half life (t1/2)

    Time frame: Up to 136 Days

  4. PD endpoint: absolute and relative change values of coagulation factor XI (FXI) activity

    Time frame: Up to 136 Days

  5. PD endpoint: absolute and relative change values of activated partial thromboplastin time (APTT)

    Time frame: Up to 136 Days

  6. Immunogenicity endpoint: the incidence and timing of ADA positivity in SHR-2004

    Time frame: Up to 136 Days

07

Study locations

1 site
  • The second Affiliated Hospital Zhejiang University School of Mdeicine
    Hangzhou, Zhejiang 310009, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Jan 2025, 9 months.

Of 20 phase 1 interventional studies under Atrial Fibrillation, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2024
First posted
Feb 28, 2024
StartActual
Apr 10, 2024
Primary completionActual
Jan 10, 2025
CompletionActual
Jan 10, 2025
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06280768
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Apr 10, 2024
Primary completion
Jan 10, 2025
Completion
Jan 10, 2025
Last update
Aug 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-2004

Start the discussion